Company / PP&E (Net)
Neurocrine Biosciences PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$89.8M
FY2025
5-year range
$58.6M / $89.8M
FY2021-FY2025
Trend
+8.7%
vs FY2024
Sector context
#51 of 195
Health Care
What the data says
At $90M, Neurocrine Biosciences's pp&e (net) ranks #51 of 195 in the Health Care sector. PP&E (Net) has increased for 3 consecutive years, from $59M in FY2022 to $90M in FY2025.
Based on SEC 10-K filings.
$90M in FY2025 with a 5-year CAGR of +15.0%.
Improved from $71M to $90M over the past 2 years.
Health Care sector context is included.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- +15.3%
- 5-Year CAGR
- +15.0%
- 10-Year CAGR
- -
Sector benchmark
#51 of 195 in Health CareTop 26% of 195This company $89.8M Sector average $770.1M
▼
-88.3% below sector average
Key checks
Key Insights
- Neurocrine Biosciences's pp&e (net) has grown for 3 consecutive years.
- 5-year CAGR of +15.0%, indicating consistent growth.
- In FY2025, pp&e (net) increased 8.7% year-over-year.
- Ranks #51 out of 195 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $89.8M | +8.7% |
| FY2024 | $82.6M | +16.7% |
| FY2023 | $70.8M | +20.8% |
| FY2022 | $58.6M | +0.0% |
| FY2021 | $58.6M | +31.4% |
| FY2020 | $44.6M | +6.4% |
| FY2019 | $41.9M | +23.7% |
| FY2018 | $33.9M | +213.3% |
| FY2017 | $10.8M | +72.4% |
| FY2016 | $6.3M | +82.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026